radiography, and ventricular dilation with abnormally low fractional shortening on echocardiography. Many families with multiple occurrences of DCM have been reportedl-3; however, most cases occur sporadically.
In 1987, Berko and Swift4 reported a large kindred in which DCM was inherited as an X-linked dominant disorder, with 11 affected males and five manifesting carrier females (heterozygous females who manifest the disease), all of whom were mothers of affected sons. Age of onset in the males ranged from late teens to early 20s and the clinical course was rapidly progressive, resulting in death or transplantation within 1-2 years. Manifesting female carriers had late onset, usually during the fifth decade, and had slow progression of heart failure. No clinical findings of skeletal myopathy could be found, although elevated muscle creatine kinase (MM-CK) did occur ( Table 1) . Molecular 60 18
Mild congestive heart failure over 10 years CK, creatine kinase; LVEDD, left ventricular end-diastolic dimension; LVEDP, left ventricular end-diastolic pressure; PAP, pulmonary artery pressure; CO, cardiac output; EF, ejection fraction; XLCM, X-linked cardiomyopathy. neurofibromatosis,20-22 and long QT syndrome. 23, 24 Each disease locus has been mapped to the genome using cosegregation analysis,2526 which measures the genetic distance between DNA probes from known chromosomal locations and the gene responsible for the disease. This mapping most commonly has been performed by Southern blotting27 using genomic or cDNA probes to generate restriction fragment length polymorphisms (RFLPs),25 which are analyzed using computer programs designed for linkage analysis to generate LOD scores (i.e., the logarithm of the odds for linkage versus the odds against linkage be 1:10,000 population. Allele frequency for each probe is shown in the "Appendix." Multiplex PCR was performed in an automated thermal cycler (Perkin-Elmer Cetus) for 25 cycles using the method described by Chamberlain et al. 43 Polymorphisms were generated by PCR in the dystrophin gene using the protocols described by Roberts et was recorded as a percentage of the absorbance in the normal control.
Results
Pedigrees XLCM-1, the truncated 63-member pedigree with X-linked DCM initially described by Berko and Swift,4 is shown in Figure 1 (top) . Affected males and manifesting female carriers are denoted. Total CK and MM-CK were elevated in all affected males and some manifesting carrier females as previously reported4 (Table 1). XLCM-2, the second pedigree evaluated ( Figure  1, bottom) , had clinical findings similar to the larger family, XLCM-1. All males presented in their late teens or early 20s with signs of congestive heart failure and echocardiograms consistent with DCM. Manifesting carrier females had later onset and less severe symptoms. All affected males and obligate carrier females in XLCM-2 had CK measured; each had abnormally elevated MM-CK (Table 1) . No abnormalities were found in any other blood studies in either family, as seen in Table 2 . All phenotypic criteria for affected males and carrier females were described before establishing genotypes, and no phenotypes were changed after genotypes were obtained.
Southern Analysis and PCR Polymorphisms
All probes used have previously been mapped, and their order on the X-chromosome was known. The polymorphism demonstrated that the 3.1-kb band (allele 2) was observed in all affected males and manifesting carrier females, whereas no unaffected males possessed this allele (Figure 2A ). Other probes in the XJ (DXS206) series (XJ1.2, XJ2.3) also gave LOD scores >2.0 at 0=0 (Table 3) . Further support for linkage was provided by the proximal 5' DMD cDNA 1-2a9-7 and pERT 84-10 (DXS142) ( Table 3) . Multipoint linkage using probes 754 (DXS84), pERT 84-10, XJ1.1, XJ1.2, and pERT 87-30 (DXS164) demonstrated a combined maximum LOD score of +4.81 (Table 3 and Figure 3 ). The only recombinations noted with markers in the dystrophin region were with pERT 87-30 (DXS164) and markers distal, including P20 (DXS269) and J66H1 (DXS268), suggesting that the mutation causing XLCM lies centromeric to these markers. It is well described that the DXS164 region of the dystrophin gene is a hot spot for recombination48 and therefore this is not a surprising finding. (CA)n polymorphisms lying approximately 12 kb 3' of dystrophin exon 44 or 1 kb 3' of exon 45 yielded LOD scores of > +2.0 for intron 44 and intron 45 at 0=0 (Table 3 ). The intron 44 microsatellite repeats displayed five alleles in this family that differ by two nucleotides each ( Figure 2B ). Intron 45 microsatellite repeats displayed six alleles differing by two nucleotides each ( Figure 2C ). The LOD scores generated by an MaeIII polymorphism localized near the dystrophin gene promoter, within 30 kb of this region at Xp21.2, also supported linkage ( Figure 2D and Table  3 ). Probes flanking the dystrophin region and those located at other portions of the short arm (Xp) or long arm (Xq) of the X chromosome were excluded from linkage. A summary of the linkage data and the relation of the probes to the dystrophin region are shown in Figure 4 .
Multiplex PCR
Using the nine-primer pair PCR method described by Chamberlain et al,43 which amplifies areas of the dystrophin gene likely to contain mutations, no deletions were demonstrated ( Figure 5 ). The primers used in this method detect approximately 85% of all deletions in the dystrophin gene. 49 The addition of the five-primer pairs described by Beggs et al50 allows for description of approximately 98% of all known deletions; no deletions occurred ( Figure 6 ) using all 14 primer pairs, therefore ruling out a known deletion as the cause of disease.
Western Blot
Immunoblots were stained for total protein in each sample lane using Ponceau-S. Total protein and myosin staining was compared in all lanes, with equal concentrations of protein and myosin shown (Figures 7 and 8) . Utilizing the N-terminal dystrophin antibody, low abundance or absence of dystrophin was shown in cardiac tissue from patients with XLCM, whereas the unrelated control samples demonstrated the normal 427-kd dystrophin protein bands (Figure 7 ). Skeletal muscle samples from the same individuals demonstrated normal staining of the 427-kd dystrophin band in affected and control samples. Negative control human DMD and mdx mouse skeletal muscle had no staining with this antibody. C-terminal antibody immunoblotted to cardiac and skeletal muscle protein demonstrated normal staining of the 427-kd dystrophin band in normal control and XLCM individuals; mdx mouse skeletal muscle had no staining with this antibody (Figure 8 ). These results were reproducible using tissue from members of both XLCM-1 and XLCM-2. Densitometry confirmed these results and demonstrated equal protein loading in all lanes. Although frozen tissue is preferred, fixed tissue gave identical results.
Discussion
The gene for XLCM has been mapped in this report to the 5' portion of the dystrophin gene at the Xp21.2 region in two families (Figure 4) . Dystrophin 
